ERBB2 and gastric cancer: Several phase II studies have shown that combined therapy using anti-human epidermal growth factor receptor 2 (HER2) drugs combined with PD-1 antibody or antiangiogenic inhibitor combined with PD-1 antibody could be a potential treatment strategy in HER2-positive GC patients (50, 51).